Urinary titin N-fragment level as a marker of both extramyocellular lipid content and hepatic disease severity in steatotic liver disease

Read full text Summarise with VIRAT
Authors: Guillaume Hénin, Harmen Reyngoudt, Stéphanie André‐Dumont, Alexis Goffaux, Salomé Declerck, Corinne Picalausa, Pierre Tréfois, Étienne Danse, Maxime Nachit, Isabelle Anne Leclercq, Peter Starkel, Benjamin Marty
+2 more Nicolas Lanthier, International liver congress - EASL
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background and aims Myosteatosis is an extrahepatic characteristic of metabolic dysfunction-associated steatohepatitis, but biomarkers of muscle quality are lacking. Here, we assessed muscle fat content by a robust magnetic resonance imaging method and urinary titin N-fragment level, a marker of sarcomere degradation, in a cohort of patients with steatotic liver disease (SLD). Method Participants with SLD were prospectively recruited. Liver disease severity was assessed by vibrationcontrolled transient elastography and subsequent Agile3+ calculation. Muscle fat content was measured using single-voxel proton magnetic resonance spectroscopy (1H-MRS) on right soleus and tibialis anterior (TA) using a PRESS-sequence (Three Tesla Signa Premier, GE Healthcare®). AMARES algorithm was used to measure separately intramyocellular lipid content (IMCL) and extramyocellular lipid content (EMCL) on water-suppressed spectra (JMRUI®). Urinary titin N-fragment level was measured by enzyme-linked immunosorbent assay using a commercialized kit (IBL® Japan) and corrected for dilution by the urinary creatinine level. Results Forty-two participants with SLD (MASLD, n=17; ALD, n=25) with muscle 1H-MRS data and urinary titin level were recruited. Based on elastography, 27% (12/45) of participants were classified fibrosis grade 0-1 (F0- 1), 35% F2 (16/45), 31% F3 (14/45) and 7% F4 (3/45). In the soleus, mean IMCL and EMCL were 7.9 and 34.4 μmol/g. In the TA, mean IMCL and EMCL were 6.3 and 19.6 μmol/g respectively. No significant differences in IMCL or EMCL in either muscle were observed between the MASLD and ALD groups. Mean urinary titin N-fragment level was 51.0 pmol/Cr in the MASLD group and 58.4 pmol/Cr in the ALD group (p > 0.05 between groups). Urinary titin N-fragment level significantly correlated in the pooled SLD group with creatine kinase serum level (r = 0.42, p = 0.010), another marker of muscle mass, with soleus EMCL alone (r = 0.51, p = 0.010) and with Agile3+ score (r = 0.39, p = 0.013). Conclusion Urinary titin N-fragment level specifically correlated with soleus EMCL in SLD suggesting its potential use as a biomarker of muscle quality in this specific population. The absence of difference in muscle fat content according to SLD subtype supports the use of SLD definition from a non-hepatic perspective. The positive correlation between titin levels and Agile3+ scores once again confirms the hypothesis of a disruption in the muscle-liver axis associated with the severity of SLD.

Fields of Study & Subjects

Liver Disease Diagnosis and Treatment Advanced MRI Techniques and Applications Nutrition and Health in Aging

Publication details

Journal / source
DIAL (Catholic University of Leuven)
Publication date
1 January 2026
Language
EN